Androgen Pattern and Erectile Function in Newly Diagnosed Type 2 Diabetes
|
|
- Loraine Randall
- 5 years ago
- Views:
Transcription
1 Med. J. Cairo Univ., Vol. 84, No. 3, December: , Androgen Pattern and Erectile Function in Newly Diagnosed Type 2 Diabetes AHMED I. EL-SAKKA, M.D.*; AL-SAYED M. AL-SALAMONY, M.D.** and ABEER M. AHMED, M.D.*** The Department of Urology, Faculty of Medicine, Suez Canal University, Ismailia*, the Department of Internal Medicine, Diabetes & Endocrinology Unit, Faculty of Medicine, Mansoura University** and the Department of Biochemistry, Faculty of Medicine, Menofia University*** Abstract Background: In this study, we assessed the alteration of androgen pattern and Erectile Dysfunction (ED) in male patients with recently diagnosed type 2 diabetes mellitus T2DM. Material and Methods: 176 newly diagnosed type 2 diabetic male patients underwent laboratory investigations, involving routine chemistry [glycemic indices; FBS and HbA1C] and [lipid profile; TC, TG, LDLc and HDLc]. Also, total testosterone (tt), sex hormone binding globulin, prolactin, insulin were assayed. In addition, calculated free (ft) and bioavailable (bt) testosterone were assessed. Erectile function was evaluated utilizing International Index of Erectile Function (IIEF). Results: 21.6% and 48.3% of our diabetic patients had low total testosterone (tt) and Erectile Dysfunction (ED) respectively. There were significant associations between low total testosterone (tt), severe Erectile Dysfunction (ED) and hyperglycemia (FBS) ( 200mg/dl), poorly controlled DM (HbA1c >7%) and dyslipidemia. After adjustment of covariates, a persistent significant association between decreased total testosterone (tt) as a dependent variable and increased HbA1c as a predictor was revealed by linear regression analysis. Conclusion: Newly diagnosed type 2 diabetic patients had a high prevalence of hypogonadism and Erectile Dysfunction (ED). Severe Erectile Dysfunction (ED) and hypogonadism were significantly associated with hyperglycemia and high HbA1c in recently diagnosed type 2 diabetes mellitus T2DM. Key Words: Erectile dysfunction Diabetes Androgen. Introduction HORMONAL alteration in diabetic patients is an interesting issue that was raised in the recent years [1]. Although, androgens alteration may have del- Correspondence to: Dr. Al-Sayed M. Al-Salamony, ssalamony2002@yahoo.com eterious effects on glycemic control and ultimately therapeutic strategy and prognosis of type 2 diabetes mellitus (DM), this effect is not studied in newly diagnosed type 2 DM. The endocrine society of clinical practice in their guideline recommended measurement of testosterone concentration in patients with type 2 DM due to the high prevalence of low testosterone level in those patients [2]. Hyperinsulinemia and increased glucose concentration are both negatively correlated with total (tt) and free (ft) testosterone levels in men [3]. Although several studies had reported that low level of testosterone played a role in the development of insulin resistance and type 2 DM [4], however the cause effect relationship between decreased testosterone and type 2 DM remains unsettled. Recently, investigators have demonstrated that, there were significant associations between low level of tt or Dehydroepiandrosterone Sulphate (DHEA-S) and poor control of DM [5]. Furthermore, the influence of DM control and subsequent androgen amelioration on the severity of Erectile Dysfunction (ED) was demonstrated [6]. Numerous studies have focused on the association between ED and long-standing type 2 DM [7] ; nevertheless, identifying patients who are at high risk for ED prior to or early at the time of type 2 DM diagnosis had not properly investigated. This study was designed to address the change of androgen pattern and erectile function in men at the time of type 2 DM diagnosis. Material and Methods Research design: This is a cross sectional officebased study. From January 2012 to December 2013, 341
2 342 Androgen Pattern & ED in Newly Diagnosed Type 2 DM included 176 newly diagnosed (less than 3 months duration) type 2 DM male patients who visited our Andrology Clinic at Diabetes and Endocrinology Center, at Al-Noor Specialized Hospital, Holly Makkah, KSA. (For routine assessment of erectile function at the time of DM diagnosis) and who agreed to participate were enrolled in this study. Aim of study: To assess pattern of androgen pattern and Erectile Dysfunction (ED) in patients with newly diagnosed type 2 Diabetes Mellitus (DM). ED assessment: All patients were assessed for ED using International Index for Erectile Function (IIEF). The erectile function domain consists of questions 1 to 5 and question 15 for assessing the global erectile function. Scoring of the IIEF domain of erectile function allowed classification of each patient as having no (26-30), mild (17-25), moderate (11-16), or severe (0-10) ED [8]. History and clinical examination: A thorough sexual, medical and psychosocial history was taken and a focused physical examination was performed on every patient excluding patients with other endocrinal abnormalities or chronic diseases other than diabetes. All patients were also interviewed for socio-demographics that included age, obesity, education, occupation, marital status and smoking habit. Medical history included hypertension, ischemic heart disease, dyslipidemia, obesity and current use of medication. Whenever useful, information provided by the patients was checked with the medical records. Laboratory assessment: Patients underwent routine laboratory investigations, in addition to total testosterone (tt), Sex Hormone Binding Globulin (SHBG), prolactin and insulin assessment. Calculated free (ft) and bioavailable (bt) testosterone were also assessed. We used the electrochemiluminescence immunoassay (ECLA) according to manufacturer's instructions (Elecsys Systems 20/10 Roche diagnostics corporation, Indianapolis, IN, USA) to assess the tt, prolactin, SHBG and insulin levels in the sera of the studied patients. The laboratory reference ranges were ( µU/ml), for fasting insulin, ( nmol/L) for total testosterone and 6-44nmol/L for SHBG, and ng/dL for PRL. cft was calculated from SHBG and T using the method of Vermeulen et al., and using a computer program and web site address supplied by Dr. T. Fiers, University Hospital Ghent, Ghent, Belgium ( For cft, nmol/l was taken as the lower limit of normal [9]. Because FT is the gold standard for diagnosing hypogonadism was defined as low ft [10]. Glycemic control was measured by glycosylated hemoglobin (HbA1c) using a high-performance liquid chromatography technique on a rinsed venous blood sample. Metabolic control was rated as follow: Good ( %), Fair (6.3-7%), Poor >7%. Metabolic control was evaluated according to the glycosylated hemoglobin values, dating not more than three months before the interview. Statistical analysis: The data were analyzed using the Statistical Package of Social Science (SPSS.11.0) software program. Unpaired t-test and one-way ANOVA were used to compare means of EF-Domain, tt, ft, bt, SHBG and insulin according to other variables. Testosterone level and ED severity were compared according to non-parametric classification of the measured variables using chi-square test. Multiple regression analysis was carried out to determine the association between tt as a dependent variable and HbA1c as a predictor, with adjustment for other covariates that have possible impacts on this association, such as age, FBS, BMI, lipid profile variables and insulin level. s below 0.05 were considered significant. Results Socio-demographics: A total of 176 newly diagnosed type 2 DM male patients who visited our andrology clinic were the subject of this study. Mean age ± SD was 48.2±8.9 years. The mean ages were 47.2±9.2 and 50.3±8. 1 years for eugonadal and hypogonadal patients respectively ( p> 0.05). Of the patients, 86.4% had completed or less than secondary school education, 75.6% were overweight or obese and 42% were former or current smokers. The mean BMI were 29 ±3.9 and 35.4±4.3 in eugonadal and hypogonadal patients respectively (p<) (Table 1). ED severity, hormonal pattern and DM: Of the patients 21.6% (n=38/176), and 48.3% (n=85/176) had low tt and ED respectively. In patients with ED (n=85), 22.4% had mild, 55.3% had moderate and 23.5% had severe degree (Table 2). The mean level of EF-domain was significantly lower in hypogonadal (16.4±3.9) versus eugonadal (22.8 ± 4.3) men (p<) (Table 1). In hypogonadal there were significant lower means of tt, ft, bt and higher mean of BMI in
3 Ahmed I. El-Sakka, et al. 343 comparison to eugonadal men, (Table 1). Decreasing tt and increasing severity of ED were each significantly associated with high level of FBS ( 200mg/dl), with poor control of diabetes (HbA1c >7%) and dyslipidemia (p< for each) (Table 3). There was significant association between hyperinsulinaemia and low tt level. No significant association was detected between hyperinsulinaemia and severity of ED ( p>0.05) (Table 2). There were significant associations between decrease of EF-domain and increasing of age, BMI, FBS, HbA1c (p< for each). Also the same significant differences were detected between decrease of EF-domain and hypertension as well as dyslipidemia (p< for each) (Table 3). In a multiple regression analysis models after adjusting for confounders; age, BMI, FBS, cholesterol, triglyceride, LDL, HDL, the relation between decreased tt as a dependent variable and increase HbA1c as a predictor was significant (p<0.05) (Table 4). Table (1): Clinical and biochemical parameters of patients with normal versus low testosterone levels. Parameters Abbreviations and symbols: EF BMI FBS HbA1 c tt ft bt SHBG Eugonadal : Erectile function. : Body Mass Index. : Fasting blood Sugar. : Glycosylated hemoglobin. : Total Testosterone. : Free Testosterone. : Bioavailable Testosterone. : Sex Hormone Binding Globulin. Hypogonadal p- value Age (yrs) 47.2± ± EF-Domain 22.8± ±3.9 BMI (kg/m 2 ) 29± ± FBS (mmol/l) 7.78± ± HbA1c 7.9± ± tt (nmol/l) 16.4± ± 1.1 ft (nmol/l) 0.37± ±0.04 bt (nmol/l) 8.7±3 5.4± 1.9 SHBG (nmol/l) 30.1 ± ±5.5 Unpaired t-test was used to compare means of age, EF-Domain, BMI, FBS, HbA1c, tt, ft, bt and SHBG according to gonadal status. Significance level at p<0.05. Table (2): Pattern of total testosterone level and erectile dysfunction severity according to biochemical diagnostic variables of diabetes. Variables Pattern of testosterone Normal (N=138) Low (N=38) *pvalue No (N=91) Erectile dysfunction severity Mild (N=18) Moderate (N=47) Moderate (N=47) FBS: 6.08-<8.3mmol/L 98 (71%) 10 (26.3%) (62.6%) 11 (61.1 %) 6 (12.7%) 2 (10%) <1 1. 1mmol/L 31 (22.5%) 20 (52.6%) 25 (27.5 %) 5 (27.8%) 3 (6.4%) 2 (10%) 11.1mmol/L 9 (6.5%) 8 (21.1 %) 9 (9.9%) 2 (11.1%) 38 (80.9%) 16 (80%) HbA1c: % 31 (22.5%) 5 (13.2%) 59 (64.8%) 10 (55.6%) 5 (10.6%) 1 (5%) % 16 (11.6%) 4 (10.5%) 22 (24.2%) 6 (33.3 %) 3 (6.4%) 2 (10%) >7% 91 (65.9%) 29 (76.3%) 10 (11 %) 2 (11.1%) 39 (83%) 17 (85%) Insulin: ( µU/ml) 19.6± ± ± ± ± ± Dyslipidemia (): Cholesterol (mmol/l) 4.24± ± ± ± ± ±0.27 Triglyceride (mmol/l) ± ± ± ± ± LDL (mmol/l) 3.21± ± ± ± ± ± HDL (mmol/l) 1.06± ± ± ± ± ± Abbreviations and symbols: BMI : Body Mass Index. FBS : Fasting Blood Sugar. LDL : Low-Density Lipoprotein. HDL : High-Density Lipoprotein. HbA1c : Glycosylated hemoglobin. *χ 2 : Chi-square test. : Was used to test the relationship between categorically coded FBS, and HbA1 c according to pattern of testosterone and severity of erectile dysfunction. Unpaired t-test and one-way ANOVA were used to compare means of insulin and lipid profile according to pattern of testosterone and severity of erectile dysfunction. χ 2 *pvalue
4 344 Androgen Pattern & ED in Newly Diagnosed Type 2 DM Table (3): Comparison of erectile function domain and sex hormones means according to clinical and biochemical variables. Variables <50 Age Yrs >_50 ВМI kg/m 2 <25 <30?30 Hypertension Yes No Dyslipidemia Yes No 6.1- <150 FBS mmolll <11.1 >_ % EF-Domain 23.1± ± ± ± ± ± ± ± ± ± ± ±5.1 Total Т 14.4± : % ± ± ± ± ± ± ± ±4.6 Free Т 0.39% : ± ± :: ± ± : ±0.12 Bioavailable Т 7.6± ± ± ± ± ± ± ± ± ± ± SHBG 28.2± ± ± ± ± ± ± ± ± ± ± ± Abbreviations and symbols: FBS : Fasting Blood Sugar. EF : Erectile Function. HbAlc : Glycosylated hemoglobin. ВМІ : Body Mass Index. SHBG : Sex Hormone Binding Globulin. Unpaired t-test and one-way ANOVA were used to compare means of erectile function domain and sex hormones according to age, BМІ, hypertension, dyslipidemia, FBS and HbA1c. Table (4): Multiple regression analysis using total testosterone as a dependent variable and HЪАІс as a predictor. ± Case label Age ВМI FBS Cholesterol Triglyceride LDL HDL Insulin SHBG (nmol /L) Abbreviations and symbols: ВМІ: Body Mass Index. Coefficient ± SE LDL HDL SHBG t FBS : Fasting Blood Sugar. Multiple regression analysis was carried out to determine the association between tt as a dependent variable and HbA1c as a predictor, with adjustment for other covariates that have a possible impact on this association, age, FBS, ВМІ, lipid profile variables and insulin level ±6.6 : Low-Density Lipoprotein. : High-Density Lipoprotein. : Sex Hormone Binding Globulin ± ± HЪАІс % 6.3-7% 21.6 ± ± ± ±6.5 >7% 15.9 ± ± ±
5 Ahmed I. El-Sakka, et al. 345 Discussion In the current study, we investigated changes of erectile function and androgen pattern in men at the time of type 2 DM diagnosis. We found that 21.6% and 48.3% of patients had low tt and ED respectively at the time of type 2 DM diagnosis. It was reported that 25.2% had low tt and more than 87% had different degrees of ED severity in patients with long standing type 2 DM [5,11]. Although the prevalence of ED and low tt in patients with newly diagnosed type 2 DM is lower than in patients with well established type 2 DM, however this prevalence is considered remarkably high. In the present study, there was significant association between decrease of EF-domain and increase of age, BMI, FBS, HbA1c. In another study on the gulf region Al-Hunayan et al., reported on 323 men with newly diagnosed type 2 DM that, 31% had ED. Comparing potent men and men with ED, there were statistically significant differences for smoking, duration of smoking, hypertension, education level, BMI and serum HbA1c level. Among these, age was the most important risk factor identified [1,7]. In men with low plasma testosterone, the risk of type 2 DM is increased [12]. A systematic review and meta-analysis indicated that men with higher testosterone levels had a 42% lower risk of type 2 DM compared with men with a lower serum testosterone concentration [13]. In hypogonadal men with significant decrease in means of, tt, ft, bt, there was also decrease of EF-domain and increase in BMI in comparison to eugonadal men. There were significant associations between increased number of patients with low level of tt or severe ED and high level of FBS ( 200mg/dl), poor control of diabetes (HbA1c >7%) and dyslipidemia. Previous studies had reported that androgen deficiency in type 2 DM is commonly associated with hypogonadotropic hypogonadism [14]. It could be speculated that insulin resistance associated with type 2 DM determines a reduction of insulin action in the hypothalamus, leading to hypogonadotropic hypogonadism [15]. Elevated C-reactive protein concentrations in those patients could suggest that inflammation may play an important role in the pathogenesis of this syndrome [16]. On the other hand, administration of testosterone to hypogonadal men improves insulin sensitivity and glucose homeostasis [17]. In a double-blind placebo controlled crossover study, Kapoor et al., reported that testosterone replacement therapy in hypogonadal men with type 2 DM reduces insulin resistance, and improves both glycemic control and waist circum- ference [18]. Heufelder et al., reported that testosterone treatment improved insulin sensitivity, adiponectin, and high-sensitivity C-reactive protein and addition of testosterone to diet and exercise results in greater therapeutic improvements of glycemic control and reverses the Metabolic Syndrome (MetS) in hypogonadal patients with the MetS and newly diagnosed type 2 DM [19]. Furthermore, Corona et al., recently demonstrated that the DM associated central obesity and insulin resistance, rather than DM alone, plays the most important role in DM associated-hypogonadism [20]. In the current study; after adjusting for confounders, age, BMI, FBS, cholesterol, triglyceride, LDL, HDL, the relation between tt as a dependent variable and HbA1 c as a predictor was significant. In consistent with our results, Corrales et al., had shown that the fraction of diabetic men with subnormal levels of tt increased with age and obesity [21]. Supporting to our notion, previous reports indicated that the existence of chronic diseases subtracts 10% to 15% from the values of androgens found in men without chronic diseases [22]. Zou et al., reported that a significantly lower T/estradiol (E(2)) and SHBG level were present in MetS patients and concluded that relative hypogonadism was strongly associated with the prevalence of MetS in Japanese adult men who were newly diagnosed to have impaired glucose tolerance or type 2 DM [23]. In a more recent study Corona et al., reported that checking glucose and testosterone levels is mandatory in subjects with ED because testosterone substitution in impotent impaired fasting glucose subjects might ameliorate not only their sexual life but also their overall health [24]. In our study no significant association was detected between hyperinsulinaemia and severity of ED. This could be due to measurement error and regression dilution bias which is particularly relevant for biochemical and clinical variables in the physiologically disruptive non-equilibrium state of newly diagnosed clinical diabetes [25]. The increased risk of CV disease at the onset of type 2 DM was previously reported [13]. Due to the strong association between CV risk factors and ED, the existence of ED at the onset of DM could be highly expected. This prompted us to investigate pattern of androgen and erectile function in patients with newly diagnosed type 2 DM. Our study expands current knowledge in the sense that, as occurs in long standing type 2 diabetic men, the percentage of newly diagnosed type 2 diabetic patients with subnormal levels of tt is much higher than the non diabetic men.
6 346 Androgen Pattern & ED in Newly Diagnosed Type 2 DM This study has several limitations. First, it was a cross-sectional study so the causal pattern underlying the associations that we have claimed remained to be confirmed however, these initiatives to identify patients earlier in the natural history of type 2 DM have probably decreased the variability of many of the baseline variables measured in our study. Further, one of the problems we have in studies is the difference ranges quoted for testosterone level. In the current study we used our local lab reference of total testosterone <9.2nmol/L ( nmol/L) as a cut off level for diagnosis of hypogonadism. Second, there was no control group of patients with long standing type 2 DM or a control group of similar age, BMI and total cardiovascular risk to confirm the extent of changes in erectile function and androgen changes. However; the associations between newly diagnosed type 2 DM and increased severity of ED and hypogonadism were confirmed, even when biochemical and life-style variables were controlled for. Finally, due to its subtle prognosis, all newly diagnosed diabetic patients could have disease periods varying between 2-10 years. Therefore, exclusion of cases with micro or macro vascular complications while enrolling the newly diagnosed patients might have resonance. In this study we found that patients who had high level of FBS and HbA1c at the time of DM diagnosis had increased severity of ED and hypogonadism, even when biochemical and life-style variables were controlled. Conclusions: This study clearly demonstrated that ED and hypogonadism are prevalent among newly diagnosed type 2 DM patients. Severe ED and hypogonadism had significant associations with high level of FBS and HbA1c at the time of type 2 DM diagnosis. So we recommend to motivate health care providers and other health practitioners to discuss the issue of erectile function with newly diagnosed type 2 DM patients and be more attentive to those with suboptimal DM control. References 1- CUNNINGHAM G.R. and ROSEN R.C. : Overview of male sexual dysfunction. UpToDate. c2014. Available from: BHASIN S., CUNNINGHAM G.R., HAYES F.J., MAT- SUMOTO A.M., SNYDER P.J., SWERDLOFF R. S., et al.: Testosterone therapy in adult men with androgen deficiency syndromes: An endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab., 91: , HARRIS M.I., HADDEN W.C., KNOWLER W.C. and BENNETT P.H. : Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in US population aged years. Diabetes, 36: , BASARIA S.: Cardiovascular Disease Associated With Androgen Deprivation Therapy: Time to Give It Due Respect. Journal of Clinical Oncology, 33: , EL-SAKKA A.I., SAYED H.M. and TAYEB K.A.: Diabetes-associated androgen alteration in patients with erectile dysfunction. Int. J. Androl., 31: 602-8, EL-SAKKA A.I., SAYED HM. and TAYEB K.A.: Androgen pattern in patients with type 2 diabetes associated erectile dysfunction: Impact of metabolic control. Urology, 74: , SKELDON S.C., DETSKY A.S., GOLDENBERG L. and LAW M.R.: Erectile Dysfunction and Undiagnosed Diabetes,Hypertension, and Hypercholesterolemia. Ann. Fam. Med., 13: 331-5, ROSEN R.C., RILEY A., WAGNER G., OSTERLOH I.H., KIRKPATRICK J. and MISHRA A.: The International Index of Erectile Function (IIEF) a multidimensional scale for assessment of erectile dysfunction. Urology. Jun., 49 (6): , Copyright 1997 by Elsevier Science, Inc. 9- VERMEULEN A. ANDROPAUSE: Maturitas, 34: 5-15, VERMEULEN A. and KAUFMAN J.M.: Diagnosis of hypogonadism in the aging male. Aging Males, , EL-SAKKA A.I. and TAYEB K.A.: Erectile dysfunction risk factors in non-insulin dependent diabetic Saudi patients. J. Urol., 169: , ZITZMANN M., FABER S. and NIESCHLAG E.: Association of specific symptoms and metabolic risks with serum testosterone in older men. J. Clin. Endocrinol. Metab., 91 : , DING E.L., SONG Y., MALIK V.S. and LIU S.: Sex differences of endogenous sex hormones and risk of type 2 diabetes: A systematic review and meta-analysis. J.A.M.A., 295: , DHINDSA S., PRABHAKAR S., SETHI M., BANDYO- PADHYAY A., CHAUDHURI A. and DANDONA P.: Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetes. J. Clin. Endocrinol. Metab., 89: , BRÜNING J.C., GAUTAM D., BURKS D.J., GILLETTE J., SCHUBERT M., ORBAN P.C., et al.: Role of brain insulin receptor in control of body weight and reproduction. Science, 289: , DANDONA P., DHINDSA S., CHAUDHURI A., BHATIA V. and TOPIWALA S.: Hypogonadotrophic hypogonadism in type 2 diabetes. Aging Male, 11: 107-7, BOYANOV M.A., BONEVA Z. and CHRISTOV V.G.: Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male, 6: 1-7, KAPOOR D., GOODWIN E., CHANNER K.S. and JONES T.H.: Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity
7 Ahmed I. El-Sakka, et al. 347 and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur. J. Endocrinol., 154: , HEUFELDER A.E., SAAD F., BUNCK M.C. and GOO- REN L.: Fifty-two-Week Treatment With Diet and Exercise Plus Transdermal Testosterone Reverses the Metabolic Syndrome and Improves Glycemic Control in Men With Newly Diagnosed Type 2 Diabetes and Subnormal Plasma Testosterone. J. Androl., 30: , CORONA G., MANNUCCI E., FISHER A.D., LOTTI F., PETRONE L., BALERCIA G., et al.: Low levels of androgens in men with erectile dysfunction and obesity. J. Sex Med., 5: , CORRALES J.J., BURGO R.M., GARCA-BERROCAL B., ALMEIDA M., ALBERCA I., GONZÁLEZ-BUIT- RAGO J.M., et al.: Partial Androgen Deficiency in Aging Type 2 Diabetic Men and Its Relationship to Glycemic Control. Metabolism, 53: , FELDMAN H.A., LONGCOPE C., DERBY C.A., JO- HANNES C.B., ARAUJO A.B., COVIELLO A.D., et al.: Age trends in the level of serum testosterone and other hormones in middle-aged men: Longitudinal results from the Massachusetts Male Aging Study. J. Clin. Endocrinol. Metab., 87: , ZOU B., SASAKI H. and KUMAGAI S.: Association between Relative Hypogonadism and Metabolic Syndrome in Newly Diagnosed Adult Male Patients with Impaired Glucose Tolerance or Type 2 Diabetes Mellitus. Metab. Syndr. Relat. Disord., 2 (1): 39-48, MURALEEDHARAN V., MARSH1 H., KAPOOR D., CHANNER K.S. and HUGH T.J.: Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes. European Journal of Endocrinology, 169: , SMITH G.D. and PHILLIPS A.N.: Inflation in epidemiology: "The proof and measurement of association between two things" revisited. B.M.J., 312: , 1996.
Primary Hypogonadism In Ghanaian Men With Type 2 Diabetes Mellitus
Primary Hypogonadism In Ghanaian Men With Type 2 Diabetes Mellitus H. Asare-Anane, E.K. Ofori, F.A.Yeboah, E.A. Tagoe, S.B. Bani, A.T. Bawah, R.O Ateko Abstract-Emerging evidence links insulin resistance,
More informationThe clinical importance of testosterone in men with type 2 diabetes
22 The clinical importance of testosterone in men with type 2 diabetes GEOFF HACKETT Although the association of low testosterone with type 2 diabetes is well established, testosterone levels are not routinely
More informationErectile Dysfunction, Cardiovascular Risk and
Erectile Dysfunction, Cardiovascular Risk and Testosterone National Lipid Association (NLA) 2016 Fall Clinical Update August 26-28, 2016 Amelia Island, Fl Robert A. Kloner MD, PhD Director of the Cardiovascular
More informationErectile Dysfunction and Low Testosterone: Findings in a Cohort of Barbadian Diabetic Males
Erectile Dysfunction and Low Testosterone: Findings in a Cohort of Barbadian Diabetic Males Dr. Diane Brathwaite M.B.B.S (UWI), MRCP (London), MSc Diabetes, MSc Endocrinology Clinical Coordinator The Diabetes
More informationImpact of Physical Activity on Metabolic Change in Type 2 Diabetes Mellitus Patients
2012 International Conference on Life Science and Engineering IPCBEE vol.45 (2012) (2012) IACSIT Press, Singapore DOI: 10.7763/IPCBEE. 2012. V45. 14 Impact of Physical Activity on Metabolic Change in Type
More informationSexual Dysfunction. Jae Il Kang, Byeong Kuk Ham, Mi Mi Oh, Je Jong Kim, Du Geon Moon. DOI: /kju
www.kjurology.org DOI:10.4111/kju.2011.52.6.416 Sexual Dysfunction Correlation between Serum Total Testosterone and the AMS and IIEF Questionnaires in Patients with Erectile Dysfunction with Testosterone
More informationManaging Testosterone Deficiency: A Practical Guide. John Grantmyre MD Professor of Urology Dalhousie University
Managing Testosterone Deficiency: A Practical Guide John Grantmyre MD Professor of Urology Dalhousie University 1 2 Case Study #1 A 59-Year-Old Man with Erectile Dysfunction 3 Case History Robert is a
More informationSCIENTIFIC STUDY REPORT
PAGE 1 18-NOV-2016 SCIENTIFIC STUDY REPORT Study Title: Real-Life Effectiveness and Care Patterns of Diabetes Management The RECAP-DM Study 1 EXECUTIVE SUMMARY Introduction: Despite the well-established
More informationElevated Serum Levels of Adropin in Patients with Type 2 Diabetes Mellitus and its Association with
Elevated Serum Levels of Adropin in Patients with Type 2 Diabetes Mellitus and its Association with Insulin Resistance Mehrnoosh Shanaki, Ph.D. Assistant Professor of Clinical Biochemistry Shahid Beheshti
More informationTESTOSTERONE CONCENTRATIONS IN DIABETIC AND NON-DIABETIC OBESE MEN
Diabetes Care Publish Ahead of Print, published online March 3, 2010 TESTOSTERONE CONCENTRATIONS IN DIABETIC AND NON-DIABETIC OBESE MEN Sandeep Dhindsa, MD Michael G. Miller, Pharm.D. Cecilia L McWhirter*,
More informationTestosterone Therapy in Men An update
Testosterone Therapy in Men An update SANDEEP DHINDSA Associate Professor of Medicine Director, Division of Endocrinology and Metabolism, Saint Louis University, St. Louis, MO Presenter Disclosure None
More informationThe reality of LOH-symptoms
The reality of LOH-symptoms PRISM IV Bruges, Belgium September 25-26, 2014 Dr. Herman Leliefeld Androsmannenkliniek The Netherlands The reality of LOH symptoms male external & internal genitalia Testosterone
More informationTestosterone Concentrations in Diabetic and Nondiabetic Obese Men
Epidemiology/Health Services Research O R I G I N A L A R T I C L E Testosterone Concentrations in Diabetic and Nondiabetic Obese Men SANDEEP DHINDSA, MD 1 MICHAEL G. MILLER, PHARMD 1 CECILIA L. MCWHIRTER,
More informationUpdate on diagnosis and complications of adult and elderly male hypogonadism
Hypoandrogenism in the elderly: to treat or not to treat? 12 th Italian AME Meeting; 6 th joint Meeting with AAC Bari november 10th Update on diagnosis and complications of adult and elderly male hypogonadism
More informationPRISM Bruges June Herman Leliefeld Urologist. The Netherlands
PRISM Bruges 25-26 June 2015 Herman Leliefeld Urologist The Netherlands Guidelines EAU 2015: a rich source of Knowledge! Epidemiology/ Aetiology / Pathology Diagnostic evaluation Disease management Follow-Up
More informationObesity and Testosterone Levels in Ghanaian Men With Type 2 Diabetes
Obesity and Testosterone Levels in Ghanaian Men With Type 2 Diabetes Henry Asare-Anane, PhD, Emmanuel Ofori, MPhil, Yeboah Agyemang, PhD, Sylvester Oppong, MBChB, PhD, Emmanuel Tagoe, MPhil, Simon Bani,
More informationResults: Statistical analysis of the results showed an inverse correlation between the BMI and serum testosterone.
Original Article Obesity is an independent risk factor for low serum testosterone in adult males Mohamad Habous MD, Alaa Tealab MD, Mohamed Ali MD, Amir Abdel Raheem MD, David Ralph MD, Saleh Binsaleh
More informationTHE EFFECT OF VITAMIN-C THERAPY ON HYPERGLYCEMIA, HYPERLIPIDEMIA AND NON HIGH DENSITY LIPOPROTEIN LEVEL IN TYPE 2 DIABETES
Int. J. LifeSc. Bt & Pharm. Res. 2013 Varikasuvu Seshadri Reddy et al., 2013 Review Article ISSN 2250-3137 www.ijlbpr.com Vol. 2, No. 1, January 2013 2013 IJLBPR. All Rights Reserved THE EFFECT OF VITAMIN-C
More informationGonadal Dysfunction with Postprandial Hypertriglyceridemia is Risk Predictor of Cardiovascular Disease in Men with Type 2 Diabetes Mellitus
Iraqi JMS Published by Al-Nahrain College of Medicine ISSN 1681-6579 Email: iraqijms@colmed-alnahrain.edu.iq http://www.colmed-nahrain.edu.iq Gonadal Dysfunction with Postprandial Hypertriglyceridemia
More informationStudy of the correlation between growth hormone deficiency and serum leptin, adiponectin, and visfatin levels in adults
Study of the correlation between growth hormone deficiency and serum leptin, adiponectin, and visfatin levels in adults Z.-P. Li 1, M. Zhang 2, J. Gao 3, G.-Y. Zhou 3, S.-Q. Li 1 and Z.-M. An 3 1 Golden
More informationInfluence of testosterone replacement therapy on metabolic disorders in male patients with type 2 diabetes mellitus and androgen deficiency
Janjgava et al. European Journal of Medical Research 2014, 19:56 EUROPEAN JOURNAL OF MEDICAL RESEARCH RESEARCH Open Access Influence of testosterone replacement therapy on metabolic disorders in male patients
More informationEndocrine Update Mary T. Korytkowski MD Division of Endocrinology University of Pittsburgh
Endocrine Update 2016 Mary T. Korytkowski MD Division of Endocrinology University of Pittsburgh Disclosure of Financial Relationships Mary Korytkowski MD Honoraria British Medical Journal Diabetes Research
More informationLEPTIN AS A NOVEL PREDICTOR OF DEPRESSION IN PATIENTS WITH THE METABOLIC SYNDROME
LEPTIN AS A NOVEL PREDICTOR OF DEPRESSION IN PATIENTS WITH THE METABOLIC SYNDROME Diana A. Chirinos, Ronald Goldberg, Elias Querales-Mago, Miriam Gutt, Judith R. McCalla, Marc Gellman and Neil Schneiderman
More informationClinical Study Changes in Testosterone Levels and Sex Hormone-Binding Globulin Levels in Extremely Obese Men after Bariatric Surgery
International Endocrinology Volume 2016, Article ID 1416503, 5 pages http://dx.doi.org/10.1155/2016/1416503 Clinical Study Changes in Testosterone Levels and Sex Hormone-Binding Globulin Levels in Extremely
More informationA dro r gen e R e R p e lac a e c m e e m n e t t T her e a r p a y Androgen Replacement Therapy in the Aging O j b ecti t ve v s Male
Androgen Replacement Therapy in the Aging Male Thomas J. Walsh, MD, MS Department of Urology University of California, San Francisco Objectives 1. List 3 effects of androgens on normal male physiology.
More informationBiochemical parameters among type 2 diabetic patients complaining of erectile dysfunction
Sky Journal of Medicine and Medical Sciences Vol. 2(3), pp. 009-015, March, 2014 Available online http://www.skyjournals.org/sjmms ISSN 2315-8808 2014 Sky Journals Full Length Research Paper Biochemical
More informationStudy of Sex Hormone-Binding Globulin in Type 2 Diabetes Mellitus
Study of Sex Hormone-Binding Globulin in Type 2 Diabetes Mellitus Hatem M. Salem 1 Khaled M. Hadhoud, 1 Mohamed S. S. Saad, 1 and Ahmad Baraka 2 Departments of 1 Internal Medicine and 2 Clinical Pathology,
More informationPrevalence of Risk Factors of Erectile Dysfunction among Men with Diabetes
Bahrain Medical Bulletin, Vol. 37, No. 3, September 2015 Prevalence of Risk Factors of Erectile Dysfunction among Men with Diabetes Jameel Nasser, MD, MSc* Fatima Habib, MD, MSc* Amal Al Saad, MD* Dalal
More informationLower levels sex hormone-binding globulin independently associated with metabolic syndrome in pre-elderly and elderly men in China
Journal of Geriatric Cardiology (2013) 10: 28 33 2013 JGC All rights reserved; www.jgc301.com Research Article Open Access Lower levels sex hormone-binding globulin independently associated with metabolic
More informationThe Effect of Testosterone on Metabolic Syndrome and Type 2 Diabetes
Pacific University CommonKnowledge School of Physician Assistant Studies Theses, Dissertations and Capstone Projects 8-14-2010 The Effect of Testosterone on Metabolic Syndrome and Type 2 Diabetes Alison
More informationEfficacy of Sildenafil Citrate intreatment of Erectile Dysfunction:EffectofType2Diabetes
European Urology European Urology 46 (2004) 503 509 Efficacy of Sildenafil Citrate intreatment of Erectile Dysfunction:EffectofType2Diabetes Ahmed I. El-Sakka a,b,* a Department of Urology, Suez Canal
More informationChanges and clinical significance of serum vaspin levels in patients with type 2 diabetes
Changes and clinical significance of serum vaspin levels in patients with type 2 diabetes L. Yang*, S.J. Chen*, G.Y. Yuan, D. Wang and J.J. Chen Department of Endocrinology, Affiliated Hospital of Jiangsu
More informationDiabetes Care 34: , 2011
Pathophysiology/Complications O R I G I N A L A R T I C L E Low Estradiol Concentrations in Men With Subnormal Testosterone Concentrations and Type 2 Diabetes SANDEEP DHINDSA, MD 1,2 RICHARD FURLANETTO,
More informationtestosterone and LH concentrations in the morning ( hours) and evening ( hours).
Original Article SERUM TESTOSTERONE AND LH IN HEALTHY MEN BOYCE et al. Are published normal ranges of serum testosterone too high? Results of a cross-sectional survey of serum testosterone and luteinizing
More informationHormone Replacement Therapy
Hormone Replacement Therapy What Role Should It Play With Our Patients? Noel R. Williams MD, FACOG TESTOSTERONE FOR MEN: SALVATION OR SNAKE OIL? Definition Male hypogonadism means the testicles don't produce
More informationL ow serum testosterone is common in
Clinical Care/Education/Nutrition/Psychosocial Research O R I G I N A L A R T I C L E Testosterone Replacement in Hypogonadal Men With Type 2 Diabetes and/or Metabolic Syndrome (the TIMES2 Study) T. HUGH
More informationDiagnosis and Clinical Evaluation of Hypogonadism in Adult Patients with Obesity and Diabetes
Diagnosis and Clinical Evaluation of Hypogonadism in Adult Patients with Obesity and Diabetes Adrian Dobs, M.D., M.H.S. Professor of Medicine and Oncology The Johns Hopkins University School of Medicine
More informationAdiponectin, TG/HDL-cholesterol index and hs-crp. Predictors of insulin resistance.
ORIGINAL ARTICLE Adiponectin, TG/HDL-cholesterol index and hs-crp. Predictors of insulin resistance. Bonneau GA y Pedrozo WR 1 Ministry of Public Health, Province of Misiones, 2 School of Exact, Chemical
More informationMetabolic Syndrome Update The Metabolic Syndrome: Overview. Global Cardiometabolic Risk
Metabolic Syndrome Update 21 Marc Cornier, M.D. Associate Professor of Medicine Division of Endocrinology, Metabolism & Diabetes University of Colorado Denver Denver Health Medical Center The Metabolic
More informationThe Diabetes Link to Heart Disease
The Diabetes Link to Heart Disease Anthony Abe DeSantis, MD September 18, 2015 University of WA Division of Metabolism, Endocrinology and Nutrition Oswald Toosweet Case #1 68 yo M with T2DM Diagnosed DM
More informationKnow Your Number Aggregate Report Single Analysis Compared to National Averages
Know Your Number Aggregate Report Single Analysis Compared to National s Client: Study Population: 2242 Population: 3,000 Date Range: 04/20/07-08/08/07 Version of Report: V6.2 Page 2 Study Population Demographics
More informationROLE OF HORMONAL ASSAY IN DIAGNOSING PCOD DR GAANA SREENIVAS (JSS,MYSURU)
ROLE OF HORMONAL ASSAY IN DIAGNOSING PCOD DR GAANA SREENIVAS (JSS,MYSURU) In 1935, Stein and Leventhal described 7 women with bilateral enlarged PCO, amenorrhea or irregular menses, infertility and masculinizing
More informationHYPOGONADISM DEFINITION: PRODUCTION OF SEX HORMONES AND GERM CELLS IS INADEQUATE (ENDOCRINE SOCIETY)
HYPOGONADISM DEFINITION: PRODUCTION OF SEX HORMONES AND GERM CELLS IS INADEQUATE (ENDOCRINE SOCIETY) DEFECT OF THE REPRODUCTIVE SYSTEM THAT RESULTS IN LACK OF FUNCTION OF THE GONADS (Wikipedia) REDUCTION
More informationThe Metabolic Syndrome Update The Metabolic Syndrome Update. Global Cardiometabolic Risk
The Metabolic Syndrome Update 2018 Marc Cornier, M.D. Professor of Medicine Division of Endocrinology, Metabolism & Diabetes Anschutz Health and Wellness Center University of Colorado School of Medicine
More informationThe JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009
The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 Learning Objectives 1. Understand the role of statin therapy in the primary and secondary prevention of stroke 2. Explain
More informationORIGINAL ARTICLE Vascular risk factors and erectile dysfunction in a cohort of healthy men
(2006) 18, 489 493 & 2006 Nature Publishing Group All rights reserved 0955-9930/06 $30.00 www.nature.com/ijir ORIGINAL ARTICLE in a cohort of healthy men A Ponholzer 1, C Temml 2, M Rauchenwald 1 and S
More informationCorrelation of LV Longitudinal Strain by 2D Speckle Tracking with Cardiovascular risk in Elderly. (A pilot study of EGAT-Echo study.
Correlation of LV Longitudinal Strain by 2D Speckle Tracking with Cardiovascular risk in Elderly. (A pilot study of EGAT-Echo study.) Researcher: Dr. Atthakorn Wutthimanop, MD. Research adviser: Dr.PrinVathesathokit,
More informationCHAPTER 3 DIABETES MELLITUS, OBESITY, HYPERTENSION AND DYSLIPIDEMIA IN ADULT CENTRAL KERALA POPULATION
CHAPTER 3 DIABETES MELLITUS, OBESITY, HYPERTENSION AND DYSLIPIDEMIA IN ADULT CENTRAL KERALA POPULATION 3.1 BACKGROUND Diabetes mellitus (DM) and impaired glucose tolerance (IGT) have reached epidemic proportions
More informationSoo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital
Soo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital 1. Importance of Lowering LDL-Cholesterol in Diabetes Patients & Lipid Guidelines Prevalence of dyslipidemia in Korea Prevalence
More informationInternational Journal of Pure and Applied Sciences and Technology
Int. J. Pure Appl. Sci. Technol., 23(1) (2014), pp. 28-33 International Journal of Pure and Applied Sciences and Technology ISSN 2229-6107 Available online at www.ijopaasat.in Research Paper Evaluation
More information/04/ /0 Reprinted from Vol. 172, , August 2004 THE JOURNAL OF UROLOGY
0022-5347/04/1722-0658/0 Reprinted from Vol. 172, 658 663, August 2004 THE JOURNAL OF UROLOGY Printed in U.S.A. Copyright 2004 by AMERICAN UROLOGICAL ASSOCIATION DOI: 10.1097/01.ju.0000132389.97804.d7
More informationMetabolic Syndrome among Type-2 Diabetic Patients in Benghazi- Libya: A pilot study. Arab Medical University. Benghazi, Libya
Original Article Metabolic Syndrome among Type-2 Diabetic Patients in Benghazi- Libya: A pilot study Alshkri MM 1, Elmehdawi RR 2 1 Benghazi Diabetes Center. 2 Medical Department, Faculty of Medicine,
More informationBIOCHEMICAL TESTS FOR THE INVESTIGATION OF COMMON ENDOCRINE PROBLEMS IN THE MALE
Authoriser: Moya O Doherty Page 1 of 7 BIOCHEMICAL TESTS FOR THE INVESTIGATION OF COMMON ENDOCRINE PROBLEMS IN THE MALE The purpose of this protocol is to describe common tests used for the investigation
More informationThe Metabolic Syndrome: Is It A Valid Concept? YES
The Metabolic Syndrome: Is It A Valid Concept? YES Congress on Diabetes and Cardiometabolic Health Boston, MA April 23, 2013 Edward S Horton, MD Joslin Diabetes Center Harvard Medical School Boston, MA
More informationPrevalence of hypogonadism in male Type 2 diabetes mellitus patients with and without coronary artery disease
Original Article Prevalence of hypogonadism in male Type 2 diabetes mellitus patients with and without coronary artery disease S. V. Madhu, M. Aslam, A. J. Aiman, A. Siddiqui, S. Dwivedi Department of
More informationMETABOLIC SYNDROME IN OBESE CHILDREN AND ADOLESCENTS
Rev. Med. Chir. Soc. Med. Nat., Iaşi 2012 vol. 116, no. 4 INTERNAL MEDICINE - PEDIATRICS ORIGINAL PAPERS METABOLIC SYNDROME IN OBESE CHILDREN AND ADOLESCENTS Ana-Maria Pelin 1, Silvia Mǎtǎsaru 2 University
More informationStudy of erectile dysfunction in type-2 diabetic patients
Study of erectile dysfunction in type-2 diabetic patients 1Dr. Sumeet Garg, 2 Dr. Puneet Rijhwani, 3 Dr. Deepak Gupta, 4 Dr. Manoj Khandelwal, 5 Dr. Kamlesh Kumar, 6 Dr. Reshu Gupta* 1-5 Dept.of Medicine
More informationTestosterone therapy (TTh) prevents progression from prediabetes to type 2 diabetes (T2DM) in hypogonadal: 9-year data from a registry study
Testosterone therapy (TTh) prevents progression from prediabetes to type 2 diabetes (T2DM) in hypogonadal: 9-year data from a registry study F Saad 1,2, KS Haider 3, A Haider 3 1 Global Medical Affairs
More informationKeywords: Position statement, expert opinion, hypogonadism, men, testosterone, calculated bioavailable testosterone
The Aging Male, December 2007; 10(4): 211 216 WORKSHOP REPORT Functional testosterone: Biochemical assessment of hypogonadism in men Report from a multidisciplinary workshop hosted by the Ontario Society
More informationPreparing for the road ahead. LEARN MORE ABOUT these 5 risks
Preparing for the road ahead LEARN MORE ABOUT these 5 risks to A MAN S health 3 4 5 2 6 1 7 0 8 9 WHY DOES IT SEEM LIKE SOME MEN TAKE BETTER CARE OF THEIR CARS THAN THEIR OWN HEALTH? When the check engine
More informationPoint-Counterpoint: Late Onset Hypogonadism (LOH)
Point-Counterpoint: Late Onset Hypogonadism (LOH) We are Under-diagnosing and Treating Men with LOH LOH is a Non-existent Disease ~ Robert E. Donohue, MD Late Onset Hypogonadism LOH: underdx. & undertx
More informationAre dehydroepiandrosterone sulphate and lipids associated with erectile dysfunction?
Maturitas 50 (2005) 294 299 Are dehydroepiandrosterone sulphate and lipids associated with erectile dysfunction? Analia Tomova, Philip Kumanov Clinical Center of Endocrinology, Medical University, 6, Damian
More informationTestosterone and PDE5 inhibitors in the aging male
Testosterone and PDE5 inhibitors in the aging male Francesco Romanelli Department of Experimental Medicine Medical Pathophysiology, Food Science and Endocrinology Section Sapienza University of Rome 3005
More informationE pidemiological studies have reported
Cardiovascular and Metabolic Risk O R I G I N A L A R T I C L E Sex Hormone Binding Globulin, but Not Testosterone, Is Associated Prospectively and Independently With Incident Metabolic Syndrome in Men
More informationMetabolic Syndrome and Workplace Outcome
Metabolic Syndrome and Workplace Outcome Maine Worksite Wellness Initiative June 15, 2010 Alyssa B. Schultz Dee W. Edington Current Definition* of Metabolic Syndrome At least 3 of the following: Waist
More informationdepression, anxiety, testosterone and luteinizing hormone levels in disorders of sexual function
International Journal of Advances in Medicine Jakka NR et al. Int J Adv Med. 2017 Aug;4(4):1106-1110 http://www.ijmedicine.com pissn 2349-3925 eissn 2349-3933 Original Research Article DOI: http://dx.doi.org/10.18203/2349-3933.ijam20173241
More informationFLAWED TESTOSTERONE ANALYSIS SPURS MISLEADING MEDIA HEADLINES
http://www.lef.org/ FLAWED TESTOSTERONE ANALYSIS SPURS MISLEADING MEDIA HEADLINES By Blake Gossard, Kira Schmid, ND, Luke Huber, ND, MBA, Steven V. Joyal, MD The precipitous decline of men's testosterone
More informationPREVALENCE OF METABOLİC SYNDROME İN CHİLDREN AND ADOLESCENTS
PREVALENCE OF METABOLİC SYNDROME İN CHİLDREN AND ADOLESCENTS Mehmet Emre Atabek,MD,PhD Necmettin Erbakan University Faculty of Medicine, Department of Pediatrics, Division of Pediatric Endocrinology and
More informationCorporate Medical Policy Testosterone Pellet Implantation for Androgen Deficiency
Corporate Medical Policy Testosterone Pellet Implantation for Androgen Deficiency File Name: Origination: Last CAP Review: Next CAP Review: Last Review: testosterone_pellet_implantation_for_androgen_deficiency
More informationTestosterone and ageing: what have we learned since the Institute of Medicine report and what lies ahead?
REVIEW ARTICLE Testosterone and ageing: what have we learned since the Institute of Medicine report and what lies ahead? M. M. Miner, 1 A. D. Seftel 2 doi: 10.1111/j.1742-1241.2007.01317.x 1 Department
More informationThe Metabolic Syndrome Update The Metabolic Syndrome: Overview. Global Cardiometabolic Risk
Update 2013 Marc Cornier, M.D. Associate Professor of Medicine Division of Endocrinology, Metabolism & Diabetes Anschutz Health and Wellness Center University of Colorado School of Medicine Denver Health
More informationA study of micro vascular complications and associated risk factors in newly diagnosed patients of type 2 diabetes mellitus
International Journal of Community Medicine and Public Health Prakash B et al. Int J Community Med Public Health. 2018 Jun;5(6):2338-2343 http://www.ijcmph.com pissn 2394-6032 eissn 2394-6040 Original
More informationStatin therapy is associated with lower total but not bioavailable or free testosterone in men with type 2 diabetes.
Diabetes Care Publish Ahead of Print, published online December 29, 2008 Statins associated with lower total testosterone Statin therapy is associated with lower total but not bioavailable or free testosterone
More informationTestosterone undecanoate improves lipid profile in patients with type 1 diabetes and hypogonadotrophic hypogonadism
Endocrine 2016, 63 (1), Journal 1-10 2015 Note Advance Publication doi: 10.1507/endocrj.EJ16-0195 Testosterone undecanoate improves lipid profile in patients with type 1 diabetes and hypogonadotrophic
More informationVitamin D supplementation of professionally active adults
Vitamin D supplementation of professionally active adults VITAMIN D MINIMUM, MAXIMUM, OPTIMUM FRIDAY, SEPTEMBER 22 ND 2017 Samantha Kimball, PhD, MLT Research Director Pure North S Energy Foundation The
More informationCardiovascular Complications of Diabetes
VBWG Cardiovascular Complications of Diabetes Nicola Abate, M.D., F.N.L.A. Professor and Chief Division of Endocrinology and Metabolism The University of Texas Medical Branch Galveston, Texas Coronary
More informationTestosterone and the Prostate
Testosterone and the Prostate E. David Crawford, MD Professor of Surgery (Urology) and Radiation Oncology Head, Urologic Oncology E. David and Vicki M. Crawford Endowed Chair in Urologic Oncology University
More informationPromotive effect of comprehensive management on achieving blood glucose control in senile type 2 diabetics
Promotive effect of comprehensive management on achieving blood glucose control in senile type 2 diabetics S.-T. Yan, C.-X. Li, C.-L. Li, J. Li, Y.-H. Shao, Y. Liu, W.-W. Zhong, F.-S. Fang, B.-R. Sun and
More informationISSN: (print), (electronic)
http://informahealthcare.com/tam ISSN: 1368-5538 (print), 1473-0790 (electronic) Aging Male, 2014; 17(3): 147 154! 2014 Informa UK Ltd. DOI: 10.3109/13685538.2014.908460 ORIGINAL ARTICLE Performance of
More informationCurrent Data and Considerations Novel Testosterone Formulations
Current Data and Considerations Novel Testosterone Formulations 1 Hypogonadism: Treatment Safety and Prostate Health 2 Monitoring for Testosterone Therapy DRE 1,2 PSA Parameter Voiding/IPSS 1,2 Hemoglobin
More informationDiabetes and Cardiovascular Risks in the Polycystic Ovary Syndrome
Diabetes and Cardiovascular Risks in the Polycystic Ovary Syndrome John E. Nestler, M.D. William Branch Porter Professor of Medicine Chair, Department of Internal Medicine Virginia Commonwealth University
More informationRISK FACTORS FOR DIABETIC RETINOPATHY PROGRESSION
2015 ILEX PUBLISHING HOUSE, Bucharest, Roumania http://www.jrdiabet.ro Rom J Diabetes Nutr Metab Dis. 22(2):159-165 doi: 10.1515/rjdnmd-2015-0020 RISK FACTORS FOR DIABETIC RETINOPATHY PROGRESSION Mónika
More informationIschemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010
Ischemic Heart and Cerebrovascular Disease Harold E. Lebovitz, MD, FACE Kathmandu November 2010 Relationships Between Diabetes and Ischemic Heart Disease Risk of Cardiovascular Disease in Different Categories
More informationAssociation between Raised Blood Pressure and Dysglycemia in Hong Kong Chinese
Diabetes Care Publish Ahead of Print, published online June 12, 2008 Raised Blood Pressure and Dysglycemia Association between Raised Blood Pressure and Dysglycemia in Hong Kong Chinese Bernard My Cheung,
More informationAssociation between arterial stiffness and cardiovascular risk factors in a pediatric population
+ Association between arterial stiffness and cardiovascular risk factors in a pediatric population Maria Perticone Department of Experimental and Clinical Medicine University Magna Graecia of Catanzaro
More informationAssociation of Testosterone and Sex Hormone-Binding Globulin with Metabolic Syndrome and Insulin Resistance in Men
Diabetes Care Publish Ahead of Print, published online April 5, 2010 Testosterone and metabolic syndrome in men Association of Testosterone and Sex Hormone-Binding Globulin with Metabolic Syndrome and
More informationWelcome and Introduction
Welcome and Introduction This presentation will: Define obesity, prediabetes, and diabetes Discuss the diagnoses and management of obesity, prediabetes, and diabetes Explain the early risk factors for
More informationPeripheral insulin-like factor 3 (INSL3) concentrations are reduced in men with type 2
Page 1 of 23 Accepted Preprint first posted on 15 September 2009 as Manuscript EJE-09-0203 Peripheral insulin-like factor 3 (INSL3) concentrations are reduced in men with type 2 diabetes mellitus: effect
More informationJohn J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam
Latest Insights from the JUPITER Study John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Inflammation, hscrp, and Vascular Prevention
More informationJUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study
Panel Discussion: Literature that Should Have an Impact on our Practice: The Study Kaiser COAST 11 th Annual Conference Maui, August 2009 Robert Blumberg, MD, FACC Ralph Brindis, MD, MPH, FACC Primary
More informationOutline. Classic Androgen deficiency. Cardiovascular Risk and Testosterone Fact vs Fiction. Professor Robert I McLachlan AM, FRACP, PhD
Health Ed Brisbane Saturday 27 th October 2018 Cardiovascular Risk and Testosterone Fact vs Fiction Professor Robert I McLachlan AM, FRACP, PhD Hudson Institute of Medical Research, Monash University Department
More informationPresent and future association between obesity and hypogonadism in Italian male
ORIGINAL PAPER DOI: 10.4081/aiua.2014.1.26 Present and future association between obesity and hypogonadism in Italian male Valentina Boddi 1, Valeria Barbaro 2, Paul Mc Nieven 3, Mario Maggi 1, Carlo Maria
More informationAnalysis Plan Submission Form
Analysis Plan Submission Form DMHT : Analysis Plan #00410222 Date submitted: 03 January 2014 at 15:19:09 Date approved: Analysis Plan Title: Achievement of metabolic goals among different health insurance
More informationSexual Function in Male Patients with Metabolic Syndrome and Effective Parameters on Erectile Dysfunction
ORIGINAL ARTICLE Vol. 40 (1): 56-61, January - February, 2014 doi: 10.1590/S1677-5538.IBJU.2014.01.08 Sexual Function in Male Patients with Metabolic Syndrome and Effective Parameters on Erectile Dysfunction
More informationR. Charles Welliver, Jr.,* Herbert J. Wiser, Robert E. Brannigan, Kendall Feia, Manoj Monga and Tobias S. K ohler
Sexual Function/Infertility Validity of Midday Total Testosterone Levels in Older Men with Erectile Dysfunction R. Charles Welliver, Jr.,* Herbert J. Wiser, Robert E. Brannigan, Kendall Feia, Manoj Monga
More informationEffects of whole grain intake on weight changes, diabetes, and cardiovascular Disease
Effects of whole grain intake on weight changes, diabetes, and cardiovascular Disease Simin Liu, MD, ScD Professor of Epidemiology and Medicine Director, Center for Global Cardiometabolic Health Brown
More informationAn Idea Whose Time Has Come-Male Health Programs: An Opportunity For Clinical Expansion and Better Health
An Idea Whose Time Has Come-Male Health Programs: An Opportunity For Clinical Expansion and Better Health KEVIN R. LOUGHLIN MD,MBA Harvard Medical School Boston, MA THE WEAKER SEX-MALES LIFE EXPECTANCY
More informationMetabolic Syndrome. Shon Meek MD, PhD Mayo Clinic Florida Endocrinology
Metabolic Syndrome Shon Meek MD, PhD Mayo Clinic Florida Endocrinology Disclosure No conflict of interest No financial disclosure Does This Patient Have Metabolic Syndrome? 1. Yes 2. No Does This Patient
More informationLong-Term Testosterone Therapy in Type 2 Diabetes Is Associated with Decreasing Waist Circumference and Improving Erectile Function
Original Article pissn: 2287-4208 / eissn: 2287-4690 World J Mens Health Published online Sep 12, 2018 https://doi.org/10.5534/wjmh.180052m Long-Term Testosterone Therapy in Type 2 Diabetes Is Associated
More informationObesity, Weight Loss and Obstructive Sleep Apnea
Obesity, Weight Loss and Obstructive Sleep Apnea Gary D. Foster, Ph.D. Center for Obesity Research and Education Temple University School of Medicine Overview Sociocultural context Obesity: Prevalence
More information